Skip to main content

Table 3 Per-cycle dosimetry estimates obtained with three-, two-, and one-time-point methods (n = 279)

From: Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT

 

Absorbed dose (Gy)

Correlation vs. 3TP (r)b

Relative error vs. 3TP (%)

Biological decay

No biological decaya

Combined

 

3TPTM

2TPM

3TPTC

2TPC

3TP

2TP

1TPD3

2TP

1TPD3

2TP

1TPD3

Kidney

4.6

[2.7–6.6]

(1.6–10.5)

4.7

[2.8–6.8]

(1.6–11.1)

2.5

2.6

4.6

[2.7–6.6]

(1.6–10.5)

4.7

[2.7–6.8]

(1.6–11.1)

4.8

[2.7–7.1]

(1.4–11.6)

0.997

0.990

2.0

[− 0.6–4.9]

(− 3.4–16.0)

5.8

[− 0.4–9.2]

(− 37.7–17.0)

Bone marrowself

0.26

[0.12–0.63]

(0.05–2.08)

0.25

[0.11–0.62]

(0.04–2.18)

0.36

[0.21–0.90]

(0.17–3.84)

0.34

[0.20–0.86]

(0.16–3.88)

0.27

[0.12–0.64]

(0.05–3.84)

0.25

[0.12–0.63]

(0.04–3.88)

0.22

[0.11–0.56]

(0.04–2.41)

0.996

0.774

− 5.2

[− 11.4–0.6]

(− 21.9–14.1)

−10.0

[− 35.4–1.3]

(− 43.3–17.0)

Bone marrowcross

0.024

[0.013–0.061]

(0.004–0.159)

0.022

[0.011–0.060]

(0.003–0.155)

0.024

[0.013–0.061]

(0.004–0.159)

0.022

[0.011–0.060]

(0.003–0.155)

0.022

[0.012–0.054]

(0.003–0.122)

0.998

0.990

− 5.0

[− 12.6 to − 0.8]

(− 29.2–10.0)

−6.7

[− 16.5–1.3]

(− 35.4–9.7)

Tumormaxc

30.9

[7.5–70.8]

(0.5–277.6)

31.3

[7.8–71.9]

(0.5–271.1)

47.0

[12.1–81.0]

(2.9–120.0)

47.6

[7.4–82.6]

(2.9–121.7)

31.2

[7.4–74.1]

(0.5–277.6)

31.7

[7.6–76.0]

(0.5–271.1)

27.8

[6.8–61.4]

(0.5–215.3)

1.000

0.651

1.7

[− 0.4–3.9]

(− 3.5–14.0)

− 9.6

[− 30.4–8.0]

(− 35.9–15.6)

  1. C constant, D3 day 3, M monoexponential, TC trapezoid-constant, TM trapezoid-monoexponential, TP time point(s)
  2. Data is presented as median [interdecile range] (range)
  3. Median injected activity was 7.7 (range, 0.7–32.4) GBq
  4. aKidney, n = 1; BMself n = 30; BMcross n = 0; Tumormax n = 26
  5. bSpearman’s correlation, P < 0.0001 in all cases
  6. cn = 278